Eplerenone for Central Serous Chorioretinopathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01822561 |
Recruitment Status :
Completed
First Posted : April 2, 2013
Results First Posted : May 16, 2018
Last Update Posted : May 16, 2018
|
Sponsor:
Tufts Medical Center
Information provided by (Responsible Party):
Tufts Medical Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment |
Condition |
Central Serous Chorioretinopathy |
Intervention |
Drug: Eplerenone 50mg |
Enrollment | 17 |
Participant Flow
Recruitment Details | Patients with central serous chorioretinopathy were recruited in the ophthalmology clinic at Tufts Medical Center in Boston, MA between April 2013 and April 2017. |
Pre-assignment Details |
Arm/Group Title | Eplerenone Group | ||
---|---|---|---|
![]() |
All patients in this study received Eplerenone 50mg once daily for 4 weeks. Eplerenone 50mg: All patients received the same dose of eplerenone. |
||
Period Title: Overall Study | |||
Number of participants | Number of units (One eye from each subject was used) | ||
Started | 15 | 15 | |
Completed | 13 | 13 | |
Not Completed | 2 | 2 | |
Reason Not Completed | |||
Withdrawal by Subject | 2 |
Baseline Characteristics
Arm/Group Title | CSCR Patients Who Received Eplerenone | |
---|---|---|
![]() |
All patients were diagnosed with central serous chorioretinopathy. All patients received 50mg oral eplerenone daily for 4 weeks. | |
Overall Number of Baseline Participants | 13 | |
![]() |
2 Acute CSCR, 11 Chronic CSCR
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||
Number Analyzed | 13 participants | |
55.6 (2.3) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 13 participants | |
Female |
0 0.0%
|
|
Male |
13 100.0%
|
|
Race and Ethnicity Not Collected
[1] Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 0 participants | |
[1]
Measure Analysis Population Description: Race and Ethnicity were not collected from any participant.
|
||
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
||
United States | Number Analyzed | 13 participants |
13 100.0%
|
||
Patients with chronic CSCR
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 13 participants | |
11 84.6%
|
Outcome Measures
Adverse Events
Limitations and Caveats
The study had limited enrollment due to lack of interest on the part of potential study subjects.
More Information
Results Point of Contact
Name/Title: | Andre Witkin |
Organization: | Tufts Medical Center |
Phone: | 6176367950 |
EMail: | awitkin@tuftsmedicalcenter.org |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Tufts Medical Center |
ClinicalTrials.gov Identifier: | NCT01822561 |
Other Study ID Numbers: |
NEEC-10722 |
First Submitted: | March 25, 2013 |
First Posted: | April 2, 2013 |
Results First Submitted: | April 17, 2018 |
Results First Posted: | May 16, 2018 |
Last Update Posted: | May 16, 2018 |